Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors

European Journal of Heart Failure

Volumn 6, Issue 7, 2004, Pages 909-916

  Juhlin, Tord ^a   Björkman, Sven ^a   Gunnarsson, Bodil ^a   Fyge, Åsa ^a   Roth, Bodil ^a   Höglund, Peter ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ACE inhibitors; Aspirin; Coronary artery disease; Heart failure; NSAIDs; Renal function

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CILAZAPRIL; DICLOFENAC; DICLOFENAC POTASSIUM; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE; GLYCERYL TRINITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; POTASSIUM; RAMIPRIL; SODIUM;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSPNEA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; MALE; MICTURITION; OSMOLALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CREATININE; CROSS-OVER STUDIES; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY; MALE; MIDDLE AGED; NATRIURESIS; OSMOLAR CONCENTRATION; POTASSIUM; TIME FACTORS;

EID: 8144227308     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2004.02.005     Document Type: Article

References (38)

1. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302
2. The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 316:1987;1429-1435
3. The SAVE investigators. Effects of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med. 327:1992;669-677
4. The AIRE study investigators. Effects of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 342:1993;821-828
5. Trandalopril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandalopril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 333:1995;1670-1676
6. Gruppo Italiano per lo Studio della Sopravvivenza nell′ì nfarto Miocardico. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: pp. 1115-1122
7. Gainer J.V., Morrow J.D., Loveland A., King D.J., Brown N.J. Effect of bradykinin receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 339:1998;1285-1291
8. Dzau V.J., Packer M., Lilly L.S., Swartz S.L., Hollenberg N.K., Williams G.H. Prostaglandins in severe congestive heart failure: relation to activation of renin-angiotensin system and hyponatremia. N Engl J Med. 310:1984;347-352
9. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature. 231:1971;232-235
10. Baigent C., Collins R., Appleby P., Parish S., Sleight P., Peto R. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in a randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 collaborative group. Brit Med J. 316:1998;1337-1343
11. Parmley W.W. Pathophysiology of congestive heart failure. Am J Cardiol. 56:1984;7A-11A
12. Al-Khadra A.S., Salem D.N., Rand W.M., Udelson J.E., Smith J.J., Konstam M.A. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol. 31:1998;419-425
13. Nguyen K.N., Aursnes I., Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II. Am J Cardiol. 79:1997;115-119
14. Jones C.G., Cleland J.G.F. Meeting report: LIDO, HOPE, MOXCON, and WASH studies. Eur J Heart Failure. 1:1999;425-431
15. Guazzi M., Marenzi G., Alimento M., Contini M., Agostini P. Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. Circulation. 95:1997;1930-1936
16. Guazzi M., Pontone G., Agostoni P. Aspirin worsens exercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors. Am Heart J. 138:1999;254-260
17. Riegger G.A., Kahles H.W., Elsner D., Kromer E.P., Kochsiek K. Effects of acetylsalicylic acid on renal function in patients with chronic heart failure. Am J Med. 90:1991;571-575
18. Cleland J.G., Bulpitt C.J., Falk R.H., Findlay I.N., Oakley C.M., Murray G., et al. Is aspirin safe for patients with heart failure? Brit Heart J. 74:1995;215-219
19. Cleland J.G.F., John J., Houghton T. Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in hypertension and heart failure? Curr Opin Nephrol Hypertens. 10:2001;625-631
20. Cleland J.G.F. Is aspirin 'the weakest link' in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Prog Cardiovasc Dis. 44:2002;275-292
21. Cleland J.G.F. No reduction in cardiovascular risk with NSAIDs - including aspirin? Lancet. 359:2002;92-93
22. Kinn A.C., Elbarouni J., Seideman P., Sollevi A. The effect of diclofenac sodium on renal function. Scand J Urol Nephrol. 23:1989;153-157
23. Krutzén E., Bäck S.E., Nilsson-Ehle I., Nilsson-Ehle P. Plasma clearance of a new contrast agent, iohexol: a method for the assessment of glomerular filtration rate. J Lab Clin Med. 104:1984;955-961
24. El-Sayed Y.M., Abdel-Hameed M.E., Suleiman M.S., Najib N.M. A rapid and sensitive high-performance liquid chromatographic method for the determination of diclofenac sodium in serum and its use in pharmacokinetic studies. J Pharm Pharmacol. 40:1988;727-729
25. Nishimura H., Kubo S., Ueyama M., Kubota J., Kawamura K. Peripheral hemodynamic effects of captopril in patients with congestive heart failure. Am Heart J. 117:1989;100-105
26. Hall D., Zeitler H., Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol. 20:1992;1549-1555
27. van Wijngarden J., Smit A.J., de Graeff A., van Gilst W.H., van der Broek S.A.J., van Veldheisen D.J., et al. Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol. 23:1994;240-245
28. Baur L.H., Schipperheyn J.J., van der Laarse A., Souverijn J.H., Frolich M., de Groot A., et al. Combining salicylate and enalapril in patients with coronary artery disease and heart failure. Brit Heart J. 73:1995;227-236
29. Weksler B.B., Pett S.B., Alonso D., Richter R.C., Stelzer P., Subramanian V., et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med. 308:1983;800-805
30. Davie A.P., Love M.P., McMurray J.J.V. Even low-dose aspirin inhibits arachidonic acid-induced vasodilation in heart failure. Clin Pharmacol Ther. 67:2000;530-537
31. Patrono C. Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosages? Thromb Res. 92:(Suppl 1):1998;S7-S12
32. Anderson R.J., Berl T., McDonald K.M., Schrier R.W. Evidence for an in vivo antagonism between vasopressin and prostaglandin in the mammalian kidney. J Clin Invest. 56:1975;420-426
33. Grenier F.C., Rollins T.E., Smith W.L. Kinin-induced prostaglandin synthesis by renal papillary collecting tubule cells in culture. Am J Physiol. 241:1981;F94-F104
34. Odemuyiva O., Gilmartin D., Kenny D., Hall R.J.C. Captopril and the diuretic requirements in moderate and severe chronic heart failure. Eur Heart J. 10:1989;586-590
35. Moore N., Verschuren X., Montout C., Callens J., Kong S.X., Bégaud B. Excess costs related to non-steroidal anti-inflammatory drug utilization in general practice. Thérapie. 55:2000;133-136
36. Niccoli L., Bellino S., Cautini F. Renal tolerability of three commonly employed non-steroidal anti-inflammatory drugs in elderly patients with osteoarthritis. Clin Exp Rheumatol. 20:2002;201-207
37. Mukherjee D., Nissen S.E., Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. J Am Med Assoc. 286:2001;954-959
38. Van Hecken A., Schwartz J.I., Depre M., De Lepeleire I., Dallob A., Tanaka W., et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on COX-2 vs. COX-1 in healthy volunteers. J Clin Pharmacol. 40:2000;1109-1120